A novel approach to fighting colorectal cancer is showing promise, with researchers developing an oral vaccine designed to stimulate the immune system directly within the gut. This innovative method, utilizing a modified form of the bacterium Listeria monocytogenes, aims to generate anti-tumor cells where the cancer originates, offering a potentially more targeted and effective treatment strategy.
Colorectal cancer remains a significant global health challenge. The American Cancer Society projects over 150,000 latest diagnoses in the United States in 2026, with more than 55,000 anticipated deaths. Whereas cancer immunotherapy has emerged as a powerful tool in oncology, it currently benefits only a small proportion of colorectal cancer patients, as many tumors prove unresponsive to existing therapies. This new research, published in the Journal for the ImmunoTherapy of Cancer, offers a potential pathway to overcome this resistance.
The research, led by immunologist Brian Sheridan at Stony Brook University, builds on the established potential of Listeria as an immunotherapy agent. Previous studies have explored intravenous administration of the bacterium, but Sheridan’s team focused on an oral delivery method. This approach is designed to generate a robust anti-tumor CD8 T cell response within the gastrointestinal tissues, directly targeting the site where colorectal cancer typically develops.
“We engineered a highly attenuated strain of the bacterium by removing key virulence genes but allowing access to the intestinal immune system,” explained Sheridan, associate professor in the microbiology and immunology department at Stony Brook’s Renaissance School of Medicine. “This enabled us to stimulate an anti-tumor response without causing Listeriosis.” The attenuated strain remained localized within the intestinal tissues in mouse models, avoiding spread to other organs and minimizing side effects like weight loss.
The localized immune response is a key advantage of this method. By focusing the immune system’s attack directly on the tumor site, the vaccine minimizes damage to healthy tissues. Initial results showed the vaccine curtailed local tumor growth, but its true potential emerged when combined with existing immune checkpoint inhibitors. This combination therapy led to “profound tumor control” in the model, suggesting the vaccine can effectively activate the immune system in tumors previously resistant to standard immunotherapy, according to Sheridan.
Further investigation revealed that oral immunization, coupled with immune checkpoint inhibitors, induced the accumulation of tumor-specific CD8 T cells within the tumor environment. These specialized immune cells provide immediate and long-lasting protection against cancer cells, a response not observed with vaccination or immune checkpoint inhibitors alone. This accumulation of CD8 T cells represents a significant step towards a more durable anti-cancer immune response.
“such a strategy could significantly improve the prognosis for patients with advanced or metastatic colorectal cancer who have limited therapeutic options otherwise,” Sheridan emphasized. “this method could pave the way for a new generation of cancer vaccines that could both prevent the onset of disease and enhance the efficacy of existing immunotherapies in clinical settings.”
The study received funding from the Department of Defense, the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID), the Research Foundation for the State University of New York, and several charitable foundations.
The development of this oral vaccine represents a promising advancement in colorectal cancer treatment. While still in the early stages of research, the results suggest a potential for a more targeted and effective immunotherapy approach. Further studies will be crucial to determine the vaccine’s safety and efficacy in human clinical trials.
Disclaimer: This article provides informational content and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your thoughts on the potential of oral vaccines in cancer treatment? Share your comments below, and please share this article with your network.
